Merck & Co. Stock Issuance Proceeds increased by 234.0% to $157.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 726.3%, from $19.00M to $157.00M. Over 4 years (FY 2021 to FY 2025), Stock Issuance Proceeds shows a downward trend with a -17.8% CAGR.
Higher proceeds often correlate with employee participation in stock-based compensation programs rather than external capital raising.
Cash inflows resulting from the issuance of common stock, typically through employee stock option exercises or equity co...
Standard for large-cap companies with significant equity-based compensation programs.
proceeds_from_stock_issuance| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $42.00M | $17.00M | $134.00M | $12.00M | $97.00M | $10.00M | $265.00M | $30.00M | $82.00M | $7.00M | $6.00M | $87.00M | $73.00M | $5.00M | $12.00M | $19.00M | $12.00M | $14.00M | $47.00M | $157.00M |
| QoQ Change | — | -59.5% | +688.2% | -91.0% | +708.3% | -89.7% | >999% | -88.7% | +173.3% | -91.5% | -14.3% | >999% | -16.1% | -93.2% | +140.0% | +58.3% | -36.8% | +16.7% | +235.7% | +234.0% |
| YoY Change | — | — | — | — | +131.0% | -41.2% | +97.8% | +150.0% | -15.5% | -30.0% | -97.7% | +190.0% | -11.0% | -28.6% | +100.0% | -78.2% | -83.6% | +180.0% | +291.7% | +726.3% |